Cite

HARVARD Citation

    Schuurbiers, M. et al. (2022). Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC. Journal for immunotherapy of cancer. 10 (2), p. . [Online]. 
  
Back to record